Novo Wants a Federal Judge to Put Eli Lilly's Favorite Commercial on Ozempic (GLP-1 Beef is Back)
Ah sh*t... here we go again…
It’s my pleasure to inform you the Ozempic Wars are officially back... with Novo Nordisk unloading the clip on Eli Lilly in a brand-new lawsuit.
(I actually looked it up... and this marks the 102nd time Novo has picked up the phone and said, "Hi, I'd like to sue someone," since GLP-1s became the biggest health craze since Fitbits.)
According to the lawsuit, Lilly has been telling America that Zepbound leaves Wegovy in the dust by comparing its highest-dose treatment against an older, lower-dose version of Novo's drug.
So what are the lawyers lawyering about this time?
Well, Novo pretty much marched into federal court and said Lilly's been out here running "trust me bro" commercials that compare the strongest version of Zepbound against an older, weaker version of Wegovy.
You know, the classic "Build yourself up by tearing someone else down."
The problem, Novo says, is Lilly conveniently left out one tiny detail: Novo launched a higher-dose version of Wegovy back in March that produced weight-loss results much closer to Zepbound.
Novo says it even fired off a cease-and-desist back in April saying, "Hey... maybe stop doing that."
Lilly allegedly looked at the letter… and used it as a coaster.
So now Novo wants a judge to pull the ads, make Lilly run corrective commercials, and cough up damages while they're at it.
Which tells you everything you need to know about where this market is now.
Not long ago these companies were desperately trying to manufacture enough injections because demand was absolutely feral.
Now they're spending their time arguing over font sizes, footnotes, and whose clinical trial deserves to be on national television.
That's a lot of people potentially making treatment decisions based on a comparison Novo says is outdated.
Of course, Novo's timing is… rather peculiar.
The company just watched Eli Lilly out-earn it by 35% last quarter while its own stock has slipped around 5% this year as Zepbound keeps stealing customers one prescription at a time.
So yes... this is technically a false advertising lawsuit. It's also a company that's starting to feel the heat.
As of now, Eli Lilly hasn’t publicly responded to the lawsuit… but I have a feeling they aren’t gonna pull the commercial off Fox News without a fight.
At the time of publishing this article, Stocks.News doesn’t hold positions in companies mentioned in the article.